Citations

Clear

3030 citation(s) found for "Susan, M".

The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo‐controlled, Phase III study in patients with myelofibrosis
Verstovšek, Srđan , Levy, Richard S., Catalano, John, Deininger, Michael W. , Miller, Carole B., Silver, Richard T. , Talpaz, Moshe , Winton, Elliott F., Harvey, Jimmie H., Arcasoy, Murat O. , Lyons, Roger M. , Paquette, Ronald , Raza, Azra , Vaddi, Kris , Erickson‐Viitanen, Susan, Sandor, Victor, Kantarjian, Hagop M. , Mesa, Ruben A. , Gotlib, Jason , Gupta, Vikas , DiPersio, John F. , Hexner, Elizabeth O. , Sun, William , Verstovsek, Srdan , Talpaz, Moshe , Kantarjian, Hagop

Mayo Clinic

British Journal of Haematology | March 13, 2013 | Volume: 161 | Issue: 4 | Pages: 508-516

10.1111/bjh.12274 | PMID 23480528 Get It

SummaryMyelofibrosis (MF) patients can present with a wide spectrum of disease characteristics. We analysed the consistency of ruxolitinib efficacy across patient subgroups in the COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment (COMFORT‐I,) a double‐blind trial, where patients with intermediate‐2 or high‐risk MF were randomized to twice‐daily oral ruxolitinib (n = 155) or placebo (n = 154). Subgroups analysed included MF subtype (primary, post‐polycythaemia vera, post‐essential thrombocythaemia), age (≤65, > 65 years), International Prognostic Scoring System risk group, baseline Eastern Cooperative Oncology Group performance status (0, 1, ≥2), JAK2 V617F mutation (positive, negative), baseline haemoglobin level (≥100, <100 g/l), baseline platelet count (100–200 × 109/l, >200 × 109/l), baseline palpable spleen size (≤10, >10 cm), and baseline quartile of spleen volume and Total Symptom Score (TSS; Q1 = lowest, Q4 = highest). Mean percentage change from baseline to week 24 in spleen volume and TSS were calculated for ruxolitinib and placebo in each subgroup. Overall survival was estimated by Kaplan–Meier method according to original randomization group. In ruxolitinib‐treated patients, reductions in spleen volume and TSS and evidence of improved survival relative to placebo across subgroups were consistent with those seen in the COMFORT‐I population, confirming that ruxolitinib is an effective therapy for the spectrum of MF patients studied in COMFORT‐I.
Go Red for Women Cardiovascular Health–Screening Evaluation: The Dichotomy Between Awareness and Perception of Cardiovascular Risk in the Community
Kling, Juliana M. , Miller, Virginia , Mankad, Rekha , Wilansky, Susan , Wu, Qing , Zais, Teresa, Zarling, Kathleen K., Allison, Thomas G. , Mulvagh, Sharon L. , Kling, Juliana M , Mankad, Rekha

Mayo Clinic

Journal of Women's Health | March 12, 2013 | Volume: 22 | Issue: 3 | Pages: 210-218

10.1089/jwh.2012.3744 | PMID 23480314 Get It

Background: Cardiovascular (CV) disease is the leading cause of death in U.S. women. Although women are becoming more aware of CV disease, there remains a dichotomy between awareness and perceived risk. We sought to characterize this dichotomy in women attracted to a CV health–screening event, in order to improve strategies to reduce CV risk. Methods: During CV health events held in Rochester, Minnesota, from 2007 through 2011, 294 women underwent screening for blood chemistry, body mass index, and blood pressure. Participants also completed surveys about knowledge of CV disease, risk factors, and perceived risk. Risk level was determined from the 2011 American Heart Association Effectiveness-Based Guidelines for Women. Results: Among participants (age, mean [standard deviation], 53 [15.3] years; white, 98%), 99% were aware that CV disease is the leading cause of death in women. Almost half (47%) perceived themselves to be at personal risk, although 65% were determined to be “at risk” and 12% to be at “high risk” according to guidelines, while 22% were uncategorized. Of the 228 participants “at risk” or “high risk,” 48% and 21%, respectively, did not perceive themselves to be at any risk. Conclusions : Women attracted to CV health events were aware that CV disease is the leading cause of death for women. However, the magnitude of awareness did not directly translate into perception or understanding of actual personal risk. To decrease the rate of CV disease in women, continued efforts are needed to personalize the importance of, and the methods for reducing, CV risk factors.
Family History of Colorectal Cancer in BRAF p.V600E-Mutated Colorectal Cancer Cases
Buchanan, Daniel D. , Win, Aung Ko , Walsh, Michael D. , Walters, Rhiannon, Nagler, Belinda, Pearson, Sally‐Ann , Parry, Susan, Arnold, Julie, Winship, Ingrid , Giles, Graham G. , Lindor, Noralane M. , Potter, John D. , Rosty, Christophe , Young, Joanne , Jenkins, Mark A. , Clendenning, Mark , Macrae, Finlay , Hopper, John L. , Buchanan, Daniel D , Win, Aung K , Giles, Graham G , Jenkins, Mark A , Potter, John D , Rosty, Christophe , Winship, Ingrid M

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 6, 2013 | Volume: 22 | Issue: 5 | Pages: 917-926

10.1158/1055-9965.epi-12-1211 | PMID 23462926 Get It

Abstract Background: Previous reports suggest that relatives of colorectal cancer (CRC)-affected probands carrying the BRAF p.V600E mutation are at an increased risk of CRC and extracolonic cancers (ECC). In this study, we estimated the association between a family history of either CRC or ECC and risk of CRC with a BRAF p.V600E mutation. Methods: Population-based CRC cases (probands, ages 18–59 years at diagnosis), recruited irrespective of family cancer history, were characterized for BRAF p.V600E mutation and mismatch repair (MMR) status. ORs and 95% confidence intervals (CI) were estimated using multivariable logistic regression. Results: The 690 eligible probands showed a mean age at CRC diagnosis of 46.9 ± 7.8 years, with 313 (47.9%) reporting a family history of CRC and 53 (7.7%) that were BRAF-mutated. Probands with BRAF-mutated, MMR-proficient CRCs were less likely to have a family history of CRC than probands that were BRAF wild-type (OR, 0.46; 95% CI, 0.24–0.91; P = 0.03). For probands with a BRAF-mutated CRC, the mean age at diagnosis was greater for those with a CRC-affected first- or second-degree relative (49.3 ± 6.4 years) compared with those without a family history (43.8 ± 10.2 years; P = 0.04). The older the age at diagnosis of CRC with the BRAF p.V600E mutation, the more likely these probands were to show a family history of CRC (OR, 1.09 per year of age; 95% CI, 1.00–1.18; P = 0.04). Conclusions: Probands with early-onset, BRAF-mutated, and MMR-proficient CRC were less likely to have a family history of CRC than probands that were BRAF-wild-type. Impact: These findings provide useful insights for cancer risk assessment in families and suggest that familial or inherited factors are more important in early-onset, BRAF-wild-type CRC. Cancer Epidemiol Biomarkers Prev; 22(5); 917–26. ©2013 AACR.
Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer
Pearce, Celeste Leigh, Rossing, Mary Anne, Lee, Alice W. , Ness, Roberta B., Webb, Penelope M. , Cancer), for Australian Cancer Study (Ovarian, Group, and Australian Ovarian Cancer Study, Chenevix‐Trench, Georgia , Jordan, Susan M., Stram, Douglas, Chang‐Claude, Jenny, Hein, Rebecca, Nickels, Stefan , Lurie, Galina, Thompson, Pamela J., Carney, Michael E., Goodman, Marc T. , Moysich, Kirsten B., Høgdall, Estrid , Jensen, Allan , Goode, Ellen L. , Cunningham, Julie M. , Vierkant, Robert A. , Gayther, Simon A. , Menon, Usha , Ramus, Susan J. , Brinton, Louise A. , Wentzensen, Nicolas , Lissowska, Jolanta , García‐Closas, Montserrat , Massuger, Leon F.A.G. , Kiemeney, Lambertus A. , Altena, Anne M. van , Aben, Katja K.H. , Iversen, Edwin S., McGuire, Valerie, Moorman, Patricia G. , Pike, Malcolm C. , Sieh, Weiva , Terry, Kathryn L. , Whittemore, Alice S. , Wu, Anna H. , Schildkraut, Joellen M. , Kjær, Susanne K. , Jordan, Susan J. , Cancer), for Australian Cancer Study (Ovarian, Group, and Australian Ovarian Cancer Study, Jordan, Susan M., Fridley, Brooke L. , Weber, Rachel Palmieri , Ziogas, Argyrios , Anton‐Culver, Hoda , Gentry‐Maharaj, Aleksandra , Berchuck, Andrew , Doherty, Jennifer A. , Pharoah, Paul D.P. , Risch, Harvey A. , Stram, Daniel O. , Kiemeney, Lambertus A , Kjaer, Susanne K , Ramus, Susan J , Webb, Penelope M , Jensen, Allan , Vierkant, Robert A , Menon, Usha , Moysich, Kirsten , Lissowska, Jolanta , Sieh, Weiva , García-Closas, Montserrat , Chenevix-Trench, Georgia , Høgdall, Estrid , Goodman, Marc T

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | March 6, 2013 | Volume: 22 | Issue: 5 | Pages: 880-890

10.1158/1055-9965.epi-12-1030-t | PMID 23462924 Get It

Abstract Background: There are several well-established environmental risk factors for ovarian cancer, and recent genome-wide association studies have also identified six variants that influence disease risk. However, the interplay between such risk factors and susceptibility loci has not been studied. Methods: Data from 14 ovarian cancer case–control studies were pooled, and stratified analyses by each environmental risk factor with tests for heterogeneity were conducted to determine the presence of interactions for all histologic subtypes. A genetic “risk score” was created to consider the effects of all six variants simultaneously. A multivariate model was fit to examine the association between all environmental risk factors and genetic risk score on ovarian cancer risk. Results: Among 7,374 controls and 5,566 cases, there was no statistical evidence of interaction between the six SNPs or genetic risk score and the environmental risk factors on ovarian cancer risk. In a main effects model, women in the highest genetic risk score quartile had a 65% increased risk of ovarian cancer compared with women in the lowest [95% confidence interval (CI), 1.48–1.84]. Analyses by histologic subtype yielded risk differences across subtype for endometriosis (Phet &lt; 0.001), parity (Phet &lt; 0.01), and tubal ligation (Phet = 0.041). Conclusions: The lack of interactions suggests that a multiplicative model is the best fit for these data. Under such a model, we provide a robust estimate of the effect of each risk factor that sets the stage for absolute risk prediction modeling that considers both environmental and genetic risk factors. Further research into the observed differences in risk across histologic subtype is warranted. Cancer Epidemiol Biomarkers Prev; 22(5); 880–90. ©2013 AACR.
Genome-wide scan of healthy human connectome discovers SPON1 gene variant influencing dementia severity
Jahanshad, Neda , Rajagopalan, Priya , Hua, Xue , Hibar, Derrek P., Nir, Talia M. , Toga, Arthur W. , Jack, Clifford R., Saykin, Andrew J. , Weiner, Michael W. , Medland, Sarah E. , Montgomery, Grant W. , Hansell, Narelle K. , McMahon, Katie L. , Zubicaray, Greig I. de , Martin, Nicholas G. , Wright, Margaret J. , Thompson, Paul M. , Initiative, the Alzheimer’s Disease Neuroimaging, Aisen, Paul, Petersen, Ronald, Jagust, William J. , Trojanowski, John Q. , Toga, Arthur W., Green, Robert C., Liu, Enchi , Green, Robert C., Montine, Tom, Gamst, Anthony, Thomas, Ronald G. , Donohue, Michael, Walter, Sarah , Gessert, Devon, Sather, Tamie, Harvey, Danielle, Donohue, Michael, Kornak, John , Jack, Clifford R., Felmlee, Joel P. , Schuff, Norbert, Alexander, Gene, DeCarli, Charles , Bandy, Dan, Foster, Norm, Reiman, Eric M. , Mathis, Chet, Cairns, Nigel J. , Taylor‐Reinwald, Lisa, Trojanowki, John Q., Shaw, Les, Korecka, Magdalena , Toga, Arthur W., Crawford, Karen , Neu, Scott, Khachaturian, Zaven S., Frank, R.T., Molchan, Susan, Quinn, Joseph, Lind, Betty, Dolen, Sara, Schneider, Lon S. , Pawluczyk, Sonia, Spann, Bryan M., Brewer, James, Vanderswag, Helen, Heidebrink, Judith L. , Johnson, Kris , Doody, Rachelle S., Chowdhury, Munir , Bell, Karen L. , Carroll, Maria , Leon, Sue, Mintun, Mark A., Schneider, Stacy, Marson, Daniel , Griffith, Randall, Clark, David, Grossman, Hillel, Mitsis, Effie, Romirowsky, Aliza, deToledo‐Morrell, Leyla, Duara, Ranjan , Varon, Daniel, Roberts, Peggy, Albert, Marilyn, Onyike, Chiadi, Kielb, Stephanie , Glodzik, Lidia , Santi, Susan De , Doraiswamy, P. Murali , Petrella, Jeffrey R. , Coleman, Robert E. , Arnold, Steven E. , Karlawish, Jason H., Smith, Charles D., Jicha, Gregory A. , Hardy, Peter , Lopez, Oscar L., Oakley, MaryAnn, Simpson, Donna M., Goldstein, Bonnie S., Martin, Kim, Makino, Kelly M., Ismail, M. Saleem , Brand, Connie, Mulnard, Ruth A., Thai, Gaby , Mc-Adams-Ortiz, Catherine, Mathews, Dana, Quiceno, Mary , King, Richard, Martin-Cook, Kristen, Devous, Michael D. , Cellar, Janet S., Anderson, Heather S., Swerdlow, Russell H. , Apostolova, Liana , Lu, Po H. , Bartzokis, George, Graff‐Radford, Neill R. , Parfitt, Francine, Farlow, Martin R. , Hake, Ann Marie , Matthews, Brandy R., Herring, Scott, Dyck, Christopher H. van , Carson, Richard E. , MacAvoy, Martha G., Chertkow, Howard , Bergman, Howard , Hosein, Chris, Caldwell, Curtis, Hsiung, Ging‐Yuek Robin , Feldman, Howard J., Mudge, Benita, Assaly, Michele, Kertesz, Andrew, Rogers, John, Trost, Dick, Bernick, Charles , Munic, Donna, Mesulam, Marek-Marsel, Lipowski, Kristina, Wu, Chuang‐Kuo, Johnson, Nancy E., Sadowsky, Carl, Villena, Teresa, Johnson, Kathleen, Reynolds, Brigid, Marshall, Gad A. , Frey, Meghan , Yesavage, Jerome A. , Taylor, Joy L. , Lane, Barton , Rosen, Allyson , Tinklenberg, Jared, Sabbagh, Marwan, Belden, Christine M. , Jacobson, Sandra A. , Kowall, Neil W. , Budson, Andrew E. , Johnson, Patricia Lynn, Wolday, Saba, Bwayo, Salome K., Lerner, Alan J. , Hudson, Leon, Ogrocki, Paula, Fletcher, Evan, Olichney, John , Kittur, Smita, Borrie, Michael, Lee, T.-Y., Bartha, Robert , Asthana, Sanjay , Carlsson, Cynthia M., Preda, Adrian , Tariot, Pierre N. , Fleisher, Adam , Reeder, Stephanie, Bates, Vernice, Capote, Horacio, Rainka, Michelle, Kataki, Maria , Zimmerman, Earl A. , Celmins, Dzintra, Brown, Alice D., Blank, Karen, Anderson, Karen, Santulli, Robert B. , Schwartz, Eben S., Williamson, Jeff D. , Garg, Pradeep , Watkins, Franklin, Ott, Brian R. , Querfurth, Henry, Tremont, Geoffrey , Salloway, Stephen , Malloy, Paul, Correia, Stephen , Rosen, Howard J., Mintzer, Jacobo , Longmire, Crystal Flynn, Spicer, Kenneth, Rachinsky, Irina, Kertesz, Andrew, Drost, Dick, Lee, Ting‐Yim , Jack, Clifford R., Green, Robert C. , Initiative, the Alzheimer’s Disease Neuroimaging, Jack, Clifford R. , Toga, Arthur W., Beckett, Laurel , Green, Robert C., Morris, John C. , Green, Robert C., Donohue, Michael, Sather, Tamie, Donohue, Michael, Jack, Clifford R., Dale, Anders M. , Bernstein, Matt A. , Fox, Nick C. , Koeppe, Robert A. , Chen, Kewei , Mathis, Chet, Lee, Virginia M.‐Y. , Toga, Arthur W., Foroud, Tatiana , Potkin, Steven G. , Shen, Li , Snyder, Peter J. , Kaye, Jeffrey , Lord, Joanne L. , Villanueva-Meyer, Javier E. , Stern, Yaakov , Honig, Lawrence S. , Ances, Beau M. , Grossman, Hillel, Shah, Raj C. , Duara, Ranjan , Varón, Daniel , Rusinek, Henry , Leon, Mony J. de , Karlawish, Jason , Wolk, David A. , Porsteinsson, Anton P. , Womack, Kyle , Diaz‐Arrastia, Ramon , Weiner, Myron , Levey, Allan I. , Lah, James J. , Burns, Jeffrey M. , Silverman, Daniel H.S. , Johnson, Heather M. , Black, Sandra E. , Stefanovic, Bojana , Kertesz, Andrew, Kerwin, Diana , Martínez, Walter Fabián , Turner, Raymond Scott , Sperling, Reisa Anne , Johnson, Keith A. , Killiany, Ronald , Norbash, Alexander , Obisesan, Thomas O. , Carmichael, Owen , Johnson, Sterling C. , Nguyen, Dana R. , Reeder, Stephanie, Scharre, Douglas W. , Pearlson, Godfrey D. , Sink, Kaycee M. , Miller, Bruce L. , Finger, Elizabeth C. , Kertesz, Andrew, de Zubicaray, Greig I , Hansell, Narelle K , Saykin, Andrew J , Preda, Adrian , Martin, Nicholas G , Toga, Arthur W , Wright, Margaret J , Thompson, Paul M , Medland, Sarah E , Hsiung, Gink-Yuek , Jicha, Gregory A

Mayo Clinic

Proceedings of the National Academy of Sciences | March 5, 2013 | Volume: 110 | Issue: 12 | Pages: 4768-4773

10.1073/pnas.1216206110 | PMID 23471985 Get It

Aberrant connectivity is implicated in many neurological and psychiatric disorders, including Alzheimer’s disease and schizophrenia. However, other than a few disease-associated candidate genes, we know little about the degree to which genetics play a role in the brain networks; we know even less about specific genes that influence brain connections. Twin and family-based studies can generate estimates of overall genetic influences on a trait, but genome-wide association scans (GWASs) can screen the genome for specific variants influencing the brain or risk for disease. To identify the heritability of various brain connections, we scanned healthy young adult twins with high-field, high-angular resolution diffusion MRI. We adapted GWASs to screen the brain’s connectivity pattern, allowing us to discover genetic variants that affect the human brain’s wiring. The association of connectivity with the SPON1 variant at rs2618516 on chromosome 11 (11p15.2) reached connectome-wide, genome-wide significance after stringent statistical corrections were enforced, and it was replicated in an independent subsample. rs2618516 was shown to affect brain structure in an elderly population with varying degrees of dementia. Older people who carried the connectivity variant had significantly milder clinical dementia scores and lower risk of Alzheimer’s disease. As a posthoc analysis, we conducted GWASs on several organizational and topological network measures derived from the matrices to discover variants in and around genes associated with autism ( MACROD2 ), development ( NEDD4 ), and mental retardation ( UBE2A ) significantly associated with connectivity. Connectome-wide, genome-wide screening offers substantial promise to discover genes affecting brain connectivity and risk for brain diseases.
Brief Report: Susceptibility to Childhood‐Onset Rheumatoid Arthritis: Investigation of a Weighted Genetic Risk Score That Integrates Cumulative Effects of Variants at Five Genetic Loci
Conneely, Karen N. , Jiang, Yunxuan , Sudman, Marc , Wallace, Carol A., Brown, Milton R., Ponder, Lori, Rohani‐Pichavant, Mina, Cutler, David J. , Angeles‐Han, Sheila T. , Vogler, Larry B., Kennedy, Christine, Rouster‐Stevens, Kelly , Wise, Carol A. , Punaro, Marilynn, Reed, Ann M., Mellins, Elizabeth , Bohnsack, John F. , Glass, David N., Thompson, Susan D. , Prahalad, Sampath , Zwick, Michael E.

Mayo Clinic

Arthritis & Rheumatism | March 1, 2013 | Volume: 65 | Issue: 6 | Pages: 1663-1667

10.1002/art.37913 | PMID 23450725 Get It

ObjectiveChildren with childhood‐onset rheumatoid arthritis (RA) include those with rheumatoid factor or anti–citrullinated protein antibody–positive juvenile idiopathic arthritis. To test the hypothesis that adult‐onset RA–associated variants are also associated with childhood‐onset RA, we investigated RA‐associated variants at 5 loci in a cohort of patients with childhood‐onset RA. We also assessed the cumulative association of these variants in susceptibility to childhood‐onset RA using a weighted genetic risk score (wGRS).MethodsA total of 155 children with childhood‐onset RA and 684 healthy controls were genotyped for 5 variants in the PTPN22, TRAF1/C5, STAT4, and TNFAIP3 loci. High‐resolution HLA–DRB1 genotypes were available for 149 cases and 373 controls. We tested each locus for association with childhood‐onset RA via logistic regression. We also computed a wGRS for each subject, with weights based on the natural log of the published odds ratios (ORs) for the alleles investigated, and used logistic regression to test the wGRS for association with childhood‐onset RA.ResultsChildhood‐onset RA was associated with TNFAIP3 rs10499194 (OR 0.60 [95% confidence interval 0.44–0.83]), PTPN22 rs2476601 (OR 1.61 [95% confidence interval 1.11–2.31]), and STAT4 rs7574865 (OR 1.41 [95% confidence interval 1.06–1.87]) variants. The wGRS was significantly different between cases and controls (P < 2 × 10−16). Individuals in the third to fifth quintiles of wGRS had a significantly increased disease risk compared to baseline (individuals in the first quintile). Higher wGRS was associated with increased risk of childhood‐onset RA, especially among males.ConclusionThe magnitude and direction of the association between TNFAIP3, STAT4, and PTPN22 variants and childhood‐onset RA are similar to those observed in RA, suggesting that adult‐onset RA and childhood‐onset RA share common genetic risk factors. Using a wGRS, we have demonstrated the cumulative association of RA‐associated variants with susceptibility to childhood‐onset RA.
MR Imaging of the Breast in Patients with Invasive Lobular Carcinoma
Orel, Susan G., Heller, Rose, Reynolds, Carol, Czerniecki, Brian J. , Solin, Lawrence J., Schnall, Mitchell D. , Weinstein, Susan P.

Mayo Clinic

American Journal of Roentgenology | February 27, 2013 | Volume: 176 | Issue: 2 | Pages: 399-406

10.2214/ajr.176.2.1760399 | PMID 11159081 Get It

Effect of Ruxolitinib Therapy on Myelofibrosis-Related Symptoms and Other Patient-Reported Outcomes in COMFORT-I: A Randomized, Double-Blind, Placebo-Controlled Trial
Catalano, John, Deininger, Michael W. , Shields, Alan L. , Miller, Carole B., Silver, Richard T. , Talpaz, Moshe , Winton, Elliott F., Harvey, Jimmie H., Hare, Thomas, Erickson‐Viitanen, Susan, Sandor, Victor, Levy, Richard S., Kantarjian, Hagop M. , Verstovšek, Srđan , Mesa, Ruben A. , Gotlib, Jason , Gupta, Vikas , Sun, William , Verstovsek, Srdan , Talpaz, Moshe , Kantarjian, Hagop

Mayo Clinic

Journal of Clinical Oncology | February 20, 2013 | Volume: 31 | Issue: 10 | Pages: 1285-1292

10.1200/jco.2012.44.4489 | PMID 23423753 Get It

Purpose To assess the effects of ruxolitinib on symptom burden and quality of life (QoL) and to evaluate the ability of the modified Myelofibrosis Symptom Assessment Form (MFSAF) v2.0 to measure meaningful changes in myelofibrosis-related symptoms in patients with myelofibrosis. Patients and Methods COMFORT-I (Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment–I) is a double-blind, placebo-controlled phase III study evaluating ruxolitinib in patients with intermediate-2 or high-risk myelofibrosis. Exploratory analyses were conducted on the following patient-reported outcomes (PROs) assessments: modified MFSAF v2.0 (individual symptoms and Total Symptom Score [TSS]), European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Scale, and Patient Global Impression of Change (PGIC). Results Patients receiving ruxolitinib experienced improvements in individual myelofibrosis-related symptoms, although patients receiving placebo experienced worsening (P < .001). The majority (91%) of ruxolitinib-treated patients designated as ≥ 50% TSS responders (≥ 50% TSS improvement) self-reported their condition as either “Much improved” or “Very much improved” on the PGIC. These patients achieved significant improvements in the EORTC QLQ-C30 functional domains and Global Health Status/QoL versus patients receiving placebo, who experienced worsening on these measures (P ≤ .0135). Ruxolitinib-treated patients with a lesser degree of symptom improvement (< 50% TSS responders) also achieved improvements over placebo on these measures. The degree of spleen volume reduction with ruxolitinib correlated with improvements in TSS, PGIC, PROMIS Fatigue Scale, and EORTC Global Health Status/QoL. Ruxolitinib-treated patients who achieved a ≥ 35% reduction in spleen volume experienced the greatest improvements in these PROs. Conclusion Ruxolitinib-treated patients achieved clinically meaningful improvements in myelofibrosis-related symptoms and QoL, but patients receiving placebo reported worsening of symptoms and other PROs.
Embedding Concepts of Sex and Gender Health Differences into Medical Curricula
Miller, Virginia M. , Rice, Morrisa, Schiebinger, Londa , Jenkins, Marjorie , Werbinski, Janice L., Núñez, Ana E. , Wood, Susan F. , Viggiano, Thomas R., Shuster, Lynne T., Schiebinger, Londa

Mayo Clinic

Journal of Women's Health | February 15, 2013 | Volume: 22 | Issue: 3 | Pages: 194-202

10.1089/jwh.2012.4193 | PMID 23414074 Get It

Sex, a biological variable, and gender, a cultural variable, define the individual and affect all aspects of disease prevention, development, diagnosis, progression, and treatment. Sex and gender are essential elements of individualized medicine. However, medical education rarely considers such topics beyond the physiology of reproduction. To reduce health care disparities and to provide optimal, cost-effective medical care for individuals, concepts of sex and gender health need to become embedded into education and training of health professionals. In September 2012, Mayo Clinic hosted a 2-day workshop bringing together leading experts from 13 U.S. schools of medicine and schools of public health, Health Resources and Services Administration Office of Women's Health (HRSA OWH), the National Institutes of Health (NIH) Office of Research on Women's Health (ORWH), and the Canadian Institute of Health and Gender. The purpose of this workshop was to articulate the need to integrate sex- and gender-based content into medical education and training, to identify gaps in current medical curricula, to consider strategies to embed concepts of sex and gender health into health professional curricula, and to identify existing resources to facilitate and implement change. This report summarizes these proceedings, recommendations, and action items from the workshop.
Acute Systemic Viral Infection Masquerading as an Infiltrating Lymphoma in an Elderly Patient: A Case Report and Review of the Literature
Babiker, Hani M. , Wiedenbeck, Troy, Robetorye, Ryan S. , Acharya, Utkarsh , Wilansky, Susan , Kusne, Shimon , Wiedenbeck, Troy L. , Babiker, Hani

Mayo Clinic

Case Reports in Medicine | February 12, 2013 | Volume: 2013 | Issue: No issue available | Pages: 1-5

10.1155/2013/318358 | PMID 23476662 Get It

Primary Epstein-Barr virus (EBV) infection occurs mainly in adolescents and young adults, with more than 90% of adults having serological evidence of past infection. Primary infection in those over the age of 40 is associated with an atypical and often more severe presentation that can lead to more extensive and invasive, and often unnecessary, diagnostic testing. The incidence of severe EBV-related illness in older adults has been observed to be increasing in industrialized nations. The characteristic presentation of infectious mononucleosis (IM) syndrome in elderly patients (age > 65) is not clearly defined in the literature. Here, we describe a case of primary EBV infection in an 80-year-old female and review the literature regarding primary seroconversion in elderly patients.